VRAX Virax Biolabs Group Limited

NASDAQ
$2.24

Virax Biolabs Group Limited (VRAX) has not yet scheduled its next earnings release. The consensus earnings estimate is a loss of $1.75 per share.

Earnings Date
2nd Quarter, Sep 2026
TBD
· Before Open
Earnings Whisper
-
vs ($1.75)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Virax Biolabs Group Limited

Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection, and diagnosis of viral diseases as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. Virax Biolabs Group Limited is based in London, United Kingdom.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.